Catalog Products » DLL1/Delta1, His, Human
Manual
Manual
COAs

DLL1/Delta1, His, Human

DLL1, a Notch signaling ligand, is significantly overexpressed in ERα luminal breast cancer. Intriguingly, DLL1 overexpression correlates with poor prognosis in ERα luminal breast cancer, but not in other subtypes of breast cancer. In addition, this effect is specific to DLL1, as other Notch ligands (DLL3, JAGGED1, and JAGGED2) do not influence the clinical outcome of ERα patients. DLL1-mediated Notch signaling in breast cancer is important for tumor cell proliferation, angiogenesis, and cancer stem cell function.
$280.00
Z05223-100

Ask us a question
Product Introduction
Species Human
Protein Construction
DLL1/Delta1 (Gln18-Gly540)
Accession # NP_005609		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Biotinylated Human Notch 1, His-­Avi Tag immobilized on CM5 Chip can bind DLL1/Delta1, His, Human in SPR assay (Biacore S200). Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 57.6 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in 50mM Tris, 150mM NaCl (pH 7.5).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

DLL1/Delta1, His, Human

The purity of DLL1/Delta1, His, Human is greater than 95% as determined by SEC-HPLC. »

DLL1/Delta1, His, Human

DLL1/Delta1, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background DLL1, a Notch signaling ligand, is significantly overexpressed in ERα luminal breast cancer. Intriguingly, DLL1 overexpression correlates with poor prognosis in ERα luminal breast cancer, but not in other subtypes of breast cancer. In addition, this effect is specific to DLL1, as other Notch ligands (DLL3, JAGGED1, and JAGGED2) do not influence the clinical outcome of ERα patients. DLL1-mediated Notch signaling in breast cancer is important for tumor cell proliferation, angiogenesis, and cancer stem cell function.
Synonyms H-Delta-1; DLL1; DELTA1; DL1
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.